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ABSTRACT
BACKGROUND:
The Ketogenic Diet (KD), is a high fat, low carbohydrate dietary regimen, that has been shown
to treat a diverse array of medical conditions, most notably the seizure associated with epilepsy.
Recent studies have demonstrated that in addition to reducing seizure frequency, the KD has
antiepileptogenic effects that continue after reversal to control diet (CD). Such results indicate
that the KD does not only suppress seizures in adult mice and rats, but it is potentially effective
in attenuating long-term disease progression. Furthermore, studies on autism spectrum disorder
(ASD) in a murine mouse model (BTBR mice) found that KD treatment improved autistic
behaviors by increasing sociability in a three-chamber test and decreasing self-directed repetitive
behavior. This study will use the BTBR mouse model to determine if improvement in ASDassociated behaviors persists when animals are returned to a CD.
METHODS:
BTBR mice at 5 weeks of age were randomly assigned to one of three diet groups: CD, KD, and
KD reversal. All mice underwent three-chamber behavioral testing (a test of sociability and selfdirected repetitive behaviors in autistic models of mice) followed by two periods lasting three
weeks. During the first period, both KD group and KD reversal groups were switched to KD for
three weeks and underwent three-chamber behavioral testing. Subsequently, both groups
underwent three additional weeks of KD, however in the last 5 days of the second period the
reversal group was reverted to the CD and underwent their final three-chamber behavioral test.
Body weights and blood chemistry (glucose and ketone levels) of each mouse was measured
before treatment (five weeks of age; Test 1) as well as after three weeks of diet administration
(eight weeks of age; Test 2) and after 6 weeks of diet administration (eleven weeks of age; Test
3).
RESULTS:
Although it was expected that enhanced sociability would be observed and continue after
reversal to the CD, no significant improvements in sociability (characterized by ratio of phase 2,
preference for sociability phase, compared to phase 1, the non-social phase) were found in any
treatment group. Blood analysis revealed the hallmark characteristics of KD treatment, including
weight loss, decreased glucose, and increased β –hydroxybutyrate levels were found in the KD
and KD reversal group in Test 2. Additionally, weight glucose, β –hydroxybutyrate levels
returned to baseline levels after 5-day reversal to CD.
CONCLUSION:
Despite detected metabolic changes induced by the KD, no notable improvements in sociability
were detected when the entire sample size was analyzed. These data conflict with previous
research thus ongoing research will consider methodological differences and include additional
measures of sociability including frontal contact and self-directed repetitive behaviors.
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INTRODUCTION
Autism Spectrum Disorder
Background
Autism Spectrum Disorder (ASD) is a chronic neurodevelopmental syndrome that
emerges in early childhood and affects day to day functioning (Christensen, 2012). ASD, as
described in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), is
characterized two main symptoms; persistent social communication impairment and restricted
and repetitive patterns of behavior (Melmed &Cubells, 2016). Within the past two decades the
global prevalence of ASD has increased twentyfold; in the United States alone, the Autism and
Developmental Disabilities Monitoring (ADDM) Network estimates prevalence of 1 in 68
children aged 8 years (Simonoff et al, 2007; Jon Baio, 2010).

Impact
According to the Center for Disease Control (CDC), ASD occurs in all racial, ethnic, and
socioeconomic groups and is about 4.5 more common in males (Christensen, 2012). The
economic burden of ASD is tremendous and additive throughout life as disorders on the autistic
spectrum are lifelong conditions with both direct (medical care) and indirect costs (parental loss
in productivity). Reportedly, the total direct cost per year for children with ASD is between
$11.5-$70 billion US dollars (Lavelle et al., 2014). Moreover, the physiological and behavioral
problems associated with ASD - sleeping disturbances, tantrums, self-harm, etc. - are correlated
with poor psychological health of other family members, namely mothers (Goin-Kochel, 2007;
Hastings, 2003).
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Emergence of Autism
The medical diagnosis of autism has been used for over a century beginning in the 1900s
with the psychiatrist Eugene Bleuler. Although he studied schizophrenia, Bleuler coined the term
autism to denote the social withdrawal symptoms associated with schizophrenia (Melmed &
Cubells, 2016). In 1943, the term autism was adapted by psychiatrist, Leo Kanner, who studied
mentally disabled children. Kanner published a paper that described case studies of highly
intelligent children that were preoccupied with their own internal world and displayed Bleuler's
concept of autism. Importantly, Kanner made a distinction between the developed autism in
schizophrenic patients and children born with “infantile autism” who displayed disruptions in
emotional expression and lack of empathy (Kanner, 1943). Around this same time, Hans
Asperger discovered a condition that appeared to be a less severe form of autism which also
included high functioning intellectual abilities. However, lack of social and emotional reciprocity
and other social communication impairments among patients led to the separate diagnosis of
Asperger’s syndrome (Asperger & Firth, 1991).

Diagnostic Criteria
Autism was not incorporated into the DSM as a separate diagnostic category until the
third edition in 1987. At this point, a checklist of criteria for diagnosing autism was included and
focused on three main deficits: (a) social reciprocity, (b) communication, and (c) special
interests/repetitive behaviors. In 1994, the fourth edition of the DSM was created and included a
revised definition of autism which now fell into the overarching category of pervasive
developmental disorders (PDD). PDD included five subcategories: (a) autistic disorder; (b)
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Asperger disorder; (c) Rett’s syndrome; (d) childhood disintegrative disorder; and (e) PDD-not
otherwise specified (NOS) (Melmed &Cubells, 2016).
The most recent change to the fifth edition of the DSM was published in 2013 and
eliminated all subcategories. As of now, the previous PDD subcategories create a single
condition known as Autism Spectrum Disorder. The chart in Table 1 outlines the severity levels
that create the spectrum. Thus, ASD is not a single condition, but a collection of
neurodevelopmental disorders. There are no current physiological or diagnostic tests to
determine if individuals fall on the spectrum, only behavioral methods are available for detecting
ASD. Thus, careful parental monitoring of unusual patterns of early development is the first line
for screening for ASD (Melmed &Cubells, 2016).

Table 1: Severity levels for autism spectrum disorder (Melmed &Cubells, 2016).
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Etiology of ASD
Many studies have aimed to pinpoint the biological underpinnings of ASD, yet a known
molecular mechanism of the disorder remains unidentified. Despite this uncertainty, both genetic
and environmental factors have been shown to play a role in the pathogenesis of ASD. Studies
on siblings have been instrumental in uncovering the heritability of neurodevelopmental
disorders. A recent study found concordance rates for ASD among identical twins (that share
100% of their genetic material) to be significantly higher than concordance rates of both fraternal
twins and non-twin siblings (both share 50% of their genetic material): 80%, 30%, and 20%,
respectively (Rosenberg et al. 2009).

Genetic Role
Although the high concordance rate suggests a strong genetic role, it has been found that
autism is genetically heterogeneous, as there is only 5% of a shared genetic alteration (Voineagu
et al. 2011). Furthermore, a comprehensive study in the genomic DNA of patients with ASD
found that within their sample of 264 families, no genomic variants were identified more than
twice, suggesting genetic alterations at multiple loci can contribute to the pathogenesis of ASD
(Sebat et al, 2007). With this study in mind, Morrow et al. mapped several loci and determined
that a common mechanism that ties together the numerous distinct gene mutations is activitydependent gene expression (Morrow et al 2008). Although many different mutations are
implicated, it is the shared effect on synaptic development that may be responsible for the
symptoms of ASD. This idea is the basis of the Rare Allele-Common Disease Theory, which
proposes that rare “private mutation” within families ultimately creating a genetic susceptibility
for common higher order impairments associated with ASD (Schork et al. 2009).
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Additional studies have uncovered changes in social behavior in individuals with autism-risk
alleles that carry genetic risk factors yet are unaffected by ASD. For example, it was found that
certain identified risk alleles have been associated with higher cognitive abilities based on IQ.
This suggests a relationship between genetics and disorders on the autism spectrum, such as
Asperger syndrome (Clarke et al., 2016). Furthermore, a parent-rated scale of social and
communication impairments indicated that a genetic risk for ASD was associated with altered
behavior despite clinical diagnoses of ASD (Robinson et al., 2016). Together, these studies
suggest a genetic component of ASD that makes an individual susceptible to the disorder, yet
additional environmental influences are responsible for the actual onset of the disorder (Nardone
& Elliott, 2016).

Environmental Role
Since 1970, there has been a reported increase in the rate of diagnosed ASD within the
United States. This trend has been similarly identified in the U.K. and has fueled the idea that
some environmental factors may play a strong role in the increasing incidence of autism (Blaxill,
2004). Studies analyzing exposure to certain environments have identified many factors in
association with increased frequency of ASD diagnoses. Notably, exposure to specific
teratogens, including thalidomide and valproic acid, have been linked to an increased risk of
ASD. In the 1960s, thalidomide was prescribed to treat anxiety disorders as well as morning
sickness for pregnant women (Miller, 1991). However, it was discovered that along with
congenital disorders inducing malformation of the limbs, approximately 5% of the children
exposed to thalidomide in their prenatal environment also developed ASD (Matsuzaki et al.,
2012). Similarly, it was found that pregnant women using valproic acid to treat disorders
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including epilepsy, migraines, and bipolar disorder, had an 8.9% increased likelihood of having
have a child with ASD (Rasalam et al., 2005). Although the exact mechanism is unknown, it is
clear that thalidomide and valproic acid in the prenatal environment is associated with increased
risk of ASD.
In addition to environmental toxins, maternal diabetes, advanced parental age, low birth
weight, and multiple births are all prenatal risk factors for ASD (Hallmayer et al. 2011).
Postnatally, gastrointestinal abnormalities, viral or bacterial infection, zinc deficiencies, and
abnormal melatonin synthesis have all been associated factors of individuals with disorders on
the autistic spectrum (Grabrucker, 2012).
Recent studies regarding prenatal risk factors have led to assessment of maternal health in
relation to offspring risk for development of ASD. In a study surveying Danish births from 1980
to 2005, it was found that expectant mothers hospitalized for viral infections (i.e. flu,
chickenpox, rubella, etc) during their first trimester of pregnancy had a threefold increase in the
incidence of giving birth to a child diagnosed with ASD (Atladóttir et al., 2010). Similarly, a
report of Swedish births found a 30% increase in ASD when the mothers were hospitalized for
viral infections during pregnancy (Lee et al., 2014). However, unlike the Danish study, this
investigation reported a significant effect for an association between ASD diagnosis and viral
infection in all trimesters of pregnancy. Such studies regarding viral infections and immune
activation supports possible immune-mediated mechanisms as the biological underpinnings of
ASD.
In addition to maternal viral infection, a recent study suggests that the presence of
maternal autoimmune disorders may also be a risk factor for ASD. Atladottir et al. examined
nearly 700,000 Swedish births and discovered that children diagnosed with ASD was associated
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with maternal autoimmune disorders such as Rheumatoid Arthritis, Celiac Disease, and those
with a family history of Type 1 Diabetes (Atladóttir et al., 2009). Furthermore, an overall study
using the Swedish health registry, Keil et al. analyzed maternal health in relation to prenatal
health and discovered there was a 60% increase in the odds for developing ASD for children
born of mothers with autoimmune disorders (Keil et al., 2010). Although these studies link
maternal immune activation and the development of offspring with ASD, they do not determine
the exact mechanism.
It is speculated that immune response activation plays a role in the etiology of ASD
through epigenetics. Epigenetic regulation represents changes in gene expression by factors other
than DNA sequence (Simmons, 2008; Egger et al., 2004). As stated by Goldberg et al.,
epigenetics is a recently studied phenomenon that represents changes in the final outcome of a
locus or chromosome without changing the underlying DNA sequence (Goldberg et al., 2007).
DNA methylation and histone modification are two commonly studied epigenetic markers as
they impact gene expression without altering the sequence of DNA (Nardone and Elliott, 2014).
DNA methylation is responsible for alteration in DNA-protein interaction which increases gene
silencing and may also influence levels of gene transcription, while histone methylation modify
chromatin structure to influence patterns of gene expression (Jones & Takai, 2001; Goldberg et
al., 2007). These markers are present during brain development and are associated with periods
of neural plasticity, thus is speculated that environmental factors such as viral infections during
natal development, toxins, or maternal autoimmune disease may induce epigenetic changes that
do not alter genotype yet have a profound effect of phenotype (Spiers et al., 2015; Goldberg et
al., 2007). Ultimately, these findings suggest that both the maternal environment and external
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environmental factors play a role in epigenetic changes that may be responsible for the biological
underpinnings of ASD (Egger et al., 2004).

Neuroanatomical effects of ASD
Despite an inconclusive mechanism, research has demonstrated genetic, environmental,
and epigenetic basis of the etiology of ASD. Although the biological underpinnings remain
unclear, neuroanatomical differences have been identified. In a comprehensive case study of five
adults with ASD, post mortem ultrastructural brain tissue was studied in three core areas
implicated in the pathology of ASD: the anterior cingulate cortex, orbitofrontal cortex, and
lateral prefrontal cortices. When comparing the anterior cingulate cortex (ACC), a decrease in
diameter of long-range axons was discovered among the individuals with ASD (Casanova,
2004).
Compared with control tissue, higher density of medium and short axons within the ACC
due to increased axonal branching was discovered suggesting an over-connection of prefrontal
regions in ASD. This finding is consistent with previous studies that propose that increased
density and branching of short and medium axons is a compensatory mechanism to maintain
connectivity because of decreased long-range axons that affect signal transmission delays
(Casanova, 2004). Furthermore, the excessive cortico-cortical connectivity is inadequately
selective and poorly synchronized leading to impairments in integrating information (Courchesne
& Pierce, 2005).
Within the orbitofrontal cortex (OFC), axons of the individuals with ASD had decreased
myelin thickness which suggests decreased signal conduction speed. Within the lateral prefrontal
cortices (LPFC) no significant differences were discovered (Casanova, 2004). Together, the
ultrastructural brain findings provide an outcome of the biological mechanism that underlies
13

ASD. Inadequate long-range axons, excessive expression of short and medium axons, and
decreased myelin thickness in prefrontal regions may explain help explain the etiology of ASD
and the resulting impairments in social communication and repetitive patterns of behavior
(Zikopoulos & Barbas, 2010).

Comorbidity
Mental retardation and epilepsy are distinct neurological conditions that often co-occur
with ASD. In a comprehensive study, 30% of patients experienced no mental impairment, 30%
experienced mild to moderate impairment, while 40% experienced profound mental retardation
(Fombonne, 2003). In term of epilepsy, it was found that 40% of children diagnosed with ASD
have some form of epilepsy (Gabis et al., 2005). Other behavioral conditions associated with
ASD include hyperactivity, anxiety, depression, and sleeping disturbances (Shaw et al., 2014).
Reportedly, children with ASD have increased likelihood of experiencing a variety of ailments
that effectively worsen the core symptoms of ASD. For example, individuals with disorders on
the autistic spectrum are 1.8 times more likely to have asthma and food allergies, 1.6 times more
likely to have skin allergies, 2.5 times more likely to have severe headaches, and 3.5 times more
likely to have colitis (Melmed & Cubells, 2016).

Treatment Methods for ASD
Background
There is currently no known cure for ASD. Moreover, because it is often difficult for
clinicians to address the variable manifestations of ASD, an array of treatment methods has been
created to address the core symptoms of autism: persistent social communication impairment and
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restricted and repetitive patterns of behavior. Current treatment methods include most commonly
behavioral therapy, educational intervention, and drug treatment. A combination of early
behavioral intervention, including speech and language therapy, and educational programming is
regarded as the most common and effective treatment for ASD, targeting the core symptoms
(Autism Speaks). Drug treatments such as the atypical antipsychotic risperidone may improve
sensory motor behaviors of autism however it had no effect of social communication
impairments (McDougle et al. 2005). Alternative treatments include specific diets, mind-body
interventions, energy therapies using electromagnetic fields, and homeopathy (Lofthouse, 2012).

The Ketogenic Diet
Background
The ketogenic diet (KD) is an alternative metabolic therapy developed in the 1920s to
treat refractory epilepsy. The diet was created after Dr. Conklin, an American osteopathic
physician, found that starving the body of food reduced seizure frequency in his pediatric
patients (Freeman, Kossoff, & Hartman, 2007). It was further determined by Russell Wilder of
the Mayo Clinic in 1921 that a diet consisting of high fat-content foods, adequate protein, and
insufficient levels of carbohydrate for metabolic needs would provide appropriate nutrition, yet
mimic the biological process of starvation resulting in seizure reduction (Veech, 1004; Barborka,
1928). The original KD was composed of 4:1 lipid: non-lipid ratio with 80% fat, 15% protein,
and 5% carbohydrate (Napoli et al., 2014).
The diet was used effectively by clinicians until the 1940s when new anticonvulsant
drugs, such as Dilantin, were put on the market. It is notable that breakthrough seizures can
occur when carbohydrates are reintroduced into the diet thus strict maintenance of the KD is
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required for efficacy (Huttenlocher, 1976). With increased drug development, there was a push
from pharmaceutical companies and physicians as well to move away from seemingly stringent
treatment methods, such as the KD, and more towards drug treatments. As the KD took the
backseat to various pharmaceuticals, it was prescribed less frequently thus physicians became
less experienced with the diet. This lack of experience contributed to the misconception that the
KD did not work and was difficult to tolerate (Vining et al., 1998).
Although the KD continued to be used clinically in a handful of seizure clinics, a larger
reemergence of the KD began in the 1980s after a famous producer, Jim Abrahams founded the
Charlie Foundation to Cure Pediatric Epilepsy, named after his son with refractory epilepsy
(Vining et al., 1998). After trying multiple drug treatments for his son, Abrahams learned about
the KD and brought his son to John Hopkins Hospital to begin the metabolic therapy. Shortly
after diet administration, Abrahams was astounded that his son's seizures stopped. Amazed that a
dietary regimen could have such a profound impact on his son’s health, Abrahams began the
Charlie Foundation to spread awareness regarding the beneficial effects of the diet.
In 1994, with funding from the Charlie Foundation, a multicenter study of the efficacy of
the KD was conducted in order to create a standardized protocol for the KD and assess
outcomes. Careful analysis of 7 medical centers with a total of 51 pediatric epilepsy patients on
the KD revealed that the majority of patients that remained on the KD for one year had a up to a
90% decrease in seizures. Remarkably, each center had at least 1 patient become seizure free.
This study demonstrated that not only was the diet efficacious, but following the similar
protocols the rate of success of the KD was similar among different centers. Despite new
anticonvulsant medications, studies on the efficacy of the KD provided evidence that for children
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with refractory epilepsy the success rate of the KD exceed the efficacy of pharmaceutical
treatments (Vining et al., 1998).
Today, the Johns Hopkins Protocol still exists but has been modified since the early
1990s. Some of these modifications include: lowered lipid: non-lipid ratio, decreased caloric
intake from fat (~60-70%), and fat provided as triglycerides esterified with medium-chain fatty
acids to address deficits in carnitine metabolism (Kossoff et al., 2007; Liu et al., 2013). Studies
on pediatric children of various ages have determined that a 4:1 ratio is typically more
efficacious for younger children and a 3:1 ratio is typically more efficacious for older children
(Zupec-Kania & Spellman, 2008). Below, Tabel 2, adapted from Zupec-Kania & Spellman
(2008), shows an average day on the KD for a three year old pediatric patient.

Table 2: A typical day on the ketogenic diet for a 3-year-old child. Note that the majority of fats
are from heavy cream, vegetable oils, and butter, which represent medium and long chain
triglycerides. Adapted from Zupec-Kania & Spellman, 2008.

Ketogenic Diet Mechanism of Action:
As previously mentioned, in the early 1920s Dr. Conklin found that starvation was an
effect treatment for reduction of seizure frequency in his pediatric patients. It is generally
17

accepted that the KD mimics the chronic state of ketosis that is similarly induced by starvation.
This occurs by changing the body’s form of metabolism, switching from the use of carbohydrate
and proteins as the primary metabolic fuel to using the high fat stores (Zupec-Kania & Spellman,
2008). When glucose is not available, mitochondrial β-oxidation of fatty acids in the liver
produces ketone bodies in the form of acetoacetate and β-hydroxybutyrate (BHB) (Laffel et al.,
1990).
The biochemical metabolism of ketone bodies include ketogenesis in the liver and allows
for this fat-derived energy to be used in various organs, most notably the brain. A simple overnight fast would generate ketone bodies which would meet approximately 2-6% of the body’s
energy requirements, the rest would be provided by stores of glycogen. After a three day fast,
about 30–40% of the energy needs would be supplied by ketones (Laffel et al., 1990). In addition
to increased blood ketone levels, other metabolic effects of the KD include reduced blood
glucose and increased mitochondrial function (Ruskin et al., 2013).

Figure 1: The image outlines the metabolic pathway responsible for the production of ketone bodies
during fasting or treatment with the KD. During fasting and KD there is increased acetoacetate, acetone,
and β-hydroxybutyrate (relative concentrations are present in the boxes). Due to this metabolic pathway,
presence of β-hydroxybutyrate in the blood is used to indicate successful implementation of the KD
(Bough & Rho, 2007).
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Although it has been almost a century since the diet’s conception, the exact mechanism
of the KD remains poorly understood. It has been proposed that aside from ketone metabolism,
the KD is responsible for other metabolic shifts that underlie the beneficial effects including:
modification of the tricarboxylic acid cycle to increase neurotransmitter synthesis (adenosine and
GABA), limit reactive oxygen species, and boost energy production in the brain. Such metabolic
shifts are the basis for several hypotheses for the mechanism of action of the KD (Nylen,
Likhoddii, & Burnham, 2009). Below, five of the most common hypotheses are briefly explored.
The hypotheses share many similar components but attribute the clinical effectiveness to
different biological aspects induced by the KD.

1. The Ketone Hypothesis: Research conducted by Juge et. al (2010) has noted that ketone
bodies compete with the chloride ions needed for release of the excitatory
neurotransmitter glutamate from vesicular glutamate transporters. In addition to this
suppression of neuronal excitation, ketone bodies have also been shown to enhance
receptor function of the inhibitory neurotransmitter, GABA (Yang et al., 2007). The
ability of ketone bodies to suppress glutamate and activate GABA indicates that that
ketone bodies decrease the characteristic hyperexcitability associated with seizures. This
hypothesis predicts that the ketone bodies present due to KD administration are directly
responsible for the anticonvulsant effect on the brain (Nylen, Likhoddii, & Burnham,
2009).
2. Metabolic Hypothesis: This hypothesis is rooted in the idea that ketone bodies produced
by the KD are a more efficient energy source than glucose (Nylen, Likhoddii, & Burnham,
2009). In a study conducted by Appleton and De vivo (1974), it was reported that cerebral
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energy reserves were significantly higher in their male albino rats on the KD versus a
standard control diet. Appleton and De Vivo attributed this metabolic change to a highenergy state of the brain cells from an increased ratio of ATP: ADP triggered by a high
concentration of available fats and reduced carbohydrates. In addition to refractory
epilepsy, the KD is also clinically used to treat glucose transporter protein syndrome and
pyruvate dehydrogenase deficiency, both of which result in cerebral energy failure (Nordli
& De Vivo, 1997). Additional research by Bough et al. (2006) demonstrated that
compared to control animals, mice fed the KD for three weeks had a 46% increase in
hippocampal biogenesis of mitochondria. These KD fed mice showed an up regulation of
transcription factors that encode for mitochondrial protein which suggested an increased
ATP production (Bough et al., 2006). The Metabolic Hypothesis postulates that once the
body has become accustom to enzymatic and endocrine changes that accompany the KD,
the increased activation of tricarboxylic acid cycle will increase cerebral energy via ATP
production which stabilizes neuronal membrane potential, leading to greater seizure
resistance (Zajac, et al., 2014; Bough et al., 2006).
3. Amino Acid Hypothesis: It is suggested that KD modifies the products of the tricarboxylic
acid cycle and alters the ratio of amino acid neurotransmitters, enhancing GABAergic
inhibition (Nylen, Likhoddii, & Burnham, 2009). This hypothesis is rooted in the concept
of GABA shunting, which is a regulating response thought to be mediated by the KD. In
this theory, the GABA shunting reduces the amplitude of subsequent excitatory
postsynaptic potentials and thereby reduces the hyperexcitability (McNally & Hartman,
2012). Depending upon the neuronal network, GABA may have an anticonvulsant or
proconvulsant effect, although research has indicated that cerebral GABA levels in male
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albino rats are not altered compared to rats fed a standard control diet, local or regional
GABA concentration differences may have a large effect on neuronal excitability and
thereby reduce seizure frequency (Holmes, 1995; Al-Mudallah et al., 1996).
4. Anti-Inflammatory and Lowered Reactive Oxygen Species Hypothesis: Previous
research has shown that inflammation contributes to the development of chronic epilepsy
and various other CNS diseases. Studies involving rodent models demonstrate that
induced seizures trigger an inflammatory response that enhances neuronal excitability and
propagates epileptic activity (Vezzani & Granata, 2005). Because inflammation is
mediated by reactive oxygen species which are generated by polymorphonuclear
neutrophils at the site of tissue damage, there is thought that the KD functions through an
anti-inflammatory mechanism that effectively lowers reactive oxygen species (Mittal et
al., 2014; Gasior et al., 2006). Specifically, a study by Maalouf et al. (2006) suggests that
the ketone bodies produced through KD administration may decrease mitochondrial
reactive oxygen species production by increasing mitochondrial uncoupling protein levels.
This mechanism suggests that ketone bodies are more than a fuel source but they may
have a cellular protective effect and function through an antioxidant mechanism (Kim et
al., 2007).
5. The Adenosine Hypothesis: As outlined in the Metabolic Hypothesis, the KD is thought
to increase mitochondrial biosynthesis which in turn increases cerebral energy and brain
ATP levels. The Adenosine Hypothesis is based on the observation that increased
intracellular ATP will equilibrate and result in increased extracellular concentrations of
ATP which is dephosphorylated into the neuromodulator, adenosine (Masino & Geiger,
2008). Adenosine is a molecule typically present in the extracellular space of brain tissue
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and is associated with neuronal inhibitory effects, sleep promotion, and seizure reduction
(Dunwiddie and Masino, 2001). When adenosine binds to adenosine A1/A2 receptors, it
has been shown to have an anticonvulsant effect; conversely, antagonism of A1/A2
receptors leads to stimulant effects of rodent locomotion (Marston et al., 1986). Thus, it is
thought that the KD increases adenosine A1/A2 receptor activation which hyperpolarizes
neurons, closes calcium channels, decreases excitatory glutamate release, and adequately
decreases neuronal excitability (Dunwiddie and Masino, 2001).

Proposed Connection: Ketogenic Diet and ASD
The Adenosine Hypothesis identifies key components of the neuromodulator, adenosine,
which is ubiquitous in the CNS (Dunwiddie and Masino, 2001). In addition to its role as an
anticonvulsant, researchers Poleszak and Malec identified that adenosine A2 receptor activation
attenuated amphetamine-induced stereotypy in male Wistar rats, including increases rat
grooming and increased head movements that interfere with goal-directed behavior (Polezak and
Malec, 2003; Wolgin, 2012). With the core behavioral symptoms of ASD in mind – persistent
social communication impairment and restricted and repetitive patterns of behavior – it has been
proposed that activation of adenosine receptors may aid the core symptoms of ASD (Melmed &
Cubells, 2016, Masino and Geigers, 2008). Based on the knowledge that epilepsy and ASD have
a high rate of comorbidity, a shared underlying biological mechanism of reduced adenosine has
been suggested (Brooks-Kayal, 2010). Figure 2 demonstrates the metabolic relationship between
ketone bodies (BHB and acetoacetate) and the neuromodulator, adenosine.
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Figure 2: In step 1, ketogenic metabolism yields ketone bodies which are transported to other
tissues. In the ketolytic metabolism shown step 2, the ketones have been converted into acetyl
CoA which enters the tricarboxylic acid cycle which channels protons and electrons into the
electron transport chain. In step 3, the electron transport chain drives a gradient across the outer
membrane of the mitochondria which creates ATP via ATP synthase. In step 4, a large
ATP/adenosine ratio intracellularly leads to an extracellular increase of adenosine (Masino et al.,
2009).

In 2002, a pilot study was conducted on the island of Crete to assess the role of the
ketogenic diet in 30 children (ages 4-10 years) with autistic behavior. This population was of
interest to researchers Evangeliou et al. (2003) because metabolic testing during a glucose
challenge revealed high level of ketone bodies. It was thought that individuals in the population
may have a mitochondrial energy production disturbance affecting the tricarboxylic acid cycle. If
this is the case, it is supposed that increases ketone body synthesis will be activated in order to
generate sufficient ATP. At the beginning of the study all children were classified with mildmoderate (n=2) or severe ASD (n=28). Results indicated that of the patients that continued on
the KD for a 6-month period experienced marked improvement in their social behavior, speech,
hyperactivity, and other autistic behaviors (Evangeliou et al., 2003). Overall, there was a 60% of
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the children on the KD improved on the Childhood Autism Rating Scale (Evangeliou et al.,
2003).
Despite the promising results published by Evangeliou et al. (2003) suggesting the KD
could help improve the behavioral symptoms to ASD, studies on children with ASD and the KD
were not formally replicated until 2013 when researchers Herbert and Buckley conducted a case
study of a young female diagnosed with both ASD and epilepsy (Herbert & Buckley, 2013).
After pharmacological treatments failed to reduce seizures, she was switched to a gluten-free,
casein-free diet and then added a low ratio KD (1.5:1). It was found that after 14 months of diet
consumption her seizure frequency was greatly reduced and, most notably, her behavioral
symptoms of ASD were markedly reduced; her score on the Childhood Autism Rating Scale
decreased from 49 (severe autism) to 17 (score of 30 being the cutoff for ASD).
The beneficial effects of the KD have also been shown in laboratory studies with rodent
models. Ruskin et al. (2013) fed juvenile BTBR mice, a murine autistic mouse model, and a
strict 6:1 ratio of KD for three weeks. Following behavioral at 8 weeks of age, it was noted that
the KD increased social interaction in a three-chamber test of sociability as compared with mice
fed the control diet (Figure 3).

Figure 3: Results demonstrating the effect of the KD in improving behavioral symptoms in BTBR mouse
models. Notably, after only 3-5 weeks on KD, improvement in sociability and decreased repetitive
grooming behavior was found (Ruskin et al, 2013).
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KD and Diet Reversal
More recent studies have used the KD to assess its efficacy in treating a myriad of
different disorders including the behavioral symptoms of Rett syndrome, blood glucose levels
and weight loss associated with type II diabetes, and the inflammatory environment of cancer
(Evangeliou et al., 2003). Research by Lusardi et al., (2015) has considered the KD as a therapy
to halt the development of epilepsy. In their study, rodents fed the KD for fifteen weeks showed
a prolonged reduction of seizures which continued after a 4-day reversal to control diet. Methods
of detecting epigenetic markers, such as a DNA methylation assay, were used to gather total
genomic DNA from frozen tissue and assess global DNA methylation of KD and Reversal
treatment groups compared to the CD group. Specifically, Lusardi et al. (2015), characterized the
hippocampal 5-methylcytosine (5-mC) content with an ELISA based assay.
It was found that animals maintained on the CD had and increased global DNA
methylation status in whole hippocampal isolates, whereas KD-fed epileptic animals were found
to have reduced levels of DNA methylation. This reduction of global hippocampal 5-mC more
similarly resembled the methylation in CD-fed and KD-fed non-epileptic controls. Interestingly
enough, this reduction of global hippocampal 5-mC status found to be maintained in the Reversal
group over 8 weeks, after the switch back to the CD. Such results indicate that the KD does not
only suppress seizures in adult mice and rats, but it is potentially effective in attenuating longterm disease progression by its influence on epigenetics. Lusardi et al. (2015) provide evidence
that the KD has an antiepileptogenic disease modifying effect capable of preventing the further
development of epilepsy by impacting gene expression (Lusardi et al., 2015). This study
provides evidence that there is a lasting effect of the diet that persist even when rodents are
reversed to CD.
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Figure 4: The image demonstrates the antiepileptogenic effects of a KD in the rat model of
epilepsy. Experimental design is outlined in A – 6 weeks after drug induced status epilepticus,
animals were randomly assigned to KD or CD. KD reversal to (KD-CD) was implemented in
week 21. Shown in B, seizures in the KD-fed group were significantly reduced compared to
control in weeks 18–21 while still on KD and this improvement persisted in week 27–29, after
diet reversal (Lusardi et al., 2015).

Persistent Pro-Social Effect of the KD:
In this lab, a persistent effect of the diet has been noted in previous lab trials regarding
the KD and male BTBR mice. In an unpublished study, it was found that after 12 weeks of KD
administration, increased sociability was detected in mice that remained on the KD as well as
with mice that underwent a 5-day reversal to the CD. Figure 5a demonstrates the timeline of the
study, while Figures 5b and 5c outline the significant increase in pro-social behavior detected in
phase 2 of the three-chamber test that was expected with mice remaining on the KD (5b) but
unpredicted for mice reverted to the CD (5c). This suggests that like the Lusardi et al. (2105)
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study, which demonstrated lasting seizure reduction despite diet reversal, the KD may have
lasting pro-social effects that persist even when rodents are reversed to CD.

5a

5b

5d

control diet

6:1 ketogenic diet…………………..

control diet

6:1 ketogenic diet

Stay on KD (n=12)

0.8
0.7

**

0.6
0.5
0.4

phase 1

phase 2

Time in chamber with mouse
over total time in side chambers

Time in chamber with mouse
over total time in side chambers

12 wk

5c
0.8

control diet

On KD, switch to
CD 5d prior (n=13)

0.7

*

0.6
0.5
0.4

phase 1

phase 2

Figure 5: In 5a, the timeline demonstrates KD diet administration and 5-day reversal to CD with
a single behavioral test after 12 weeks and 5 days. Figures 5b and 5c show the increase in prosocial behavior detected in both KD and Reversal groups.
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THESIS OVERVIEW:
As previously mentioned, there are many methods of treatment that exist to improve the
core symptoms of autism, yet none of the various methods have been shown to reverse the
disease process. This study is interested in the improved behavioral effects of the KD on autistic
mouse models that may outlast diet consumption. This idea is rooted in the findings of Lusardi et
al. (2105), regarding prolonged antiepiletogenic effect of the KD as well as findings from our
own lab that that suggest pro-social behavior induced by the KD may have persistent effects.
With these findings in mind, it is expected that enhanced sociability will continue even after
reversal to the control diet. This will provide evidence that multiple benefits of the KD can
endure beyond the time frame of diet administration. If this expectation holds true, further
research may be done to demonstrate that the KD is more than a metabolic treatment that
ameliorates symptoms, but a therapy that modifies the course of ASD.
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MATERIALS AND METHODS
Ethics Statement
All procedures were performed in accordance with the NIH Guide for the Care and Use
of Laboratory Animals, and approved by the Animal Care and Use Committee of Trinity College
(A3869-01).

Animals
All behavioral testing was performed in adult male Black and Tan Brachyury T+ Itpr3tf/J
(BTBR) mice, a mouse model of autism (Jackson Laboratories, Bar Harbor, ME). The BTBR
strain is a result of selective inbreeding to develop the favorable phenotypic dark black fur coat
with a notable light brown underbelly. In addition to fur color, throughout their lifespan BTBR
mice have noticeable hair loss in tufted patterns due to a mutation, Itpr3tf (inositol 1,4,5triphosphate receptor 3; tufted), and they have short tail lengths due to T mutation (brachyury).
Aside from their morphology, BTBR mice exhibit several symptoms of autism including:
reduced social interactions, impaired play, low exploratory behavior, unusual vocalizations and
high anxiety as compared to other inbred strains (McFarlane, 2008; Moy, 2007, Scattoni, 2008).
Studies conducted for the Mouse Phenome Project indicate that BTBR have neurological
difference including an absent corpus callosum and a severely reduced hippocampal commissure
(Wahlsten D, 2003). These physiological differences may be the underlying causes of their
displayed symptoms of autism.
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Study Timeline
At weaning, male BTBR mice (Jackson Laboratories, Bar Harbor, ME) were housed
socially (3–6 per cage) and fed the standard rodent chow (CD; LabDiet 5001, W.F. Fisher &
Son, Somerville, NJ). At five weeks of age, cages were assigned randomly to remain on control
diet (n=11), switched to the 6:1 KD (F3666; BioServ, Frenchtown, NJ) (n=12), or the KD-CD
reversal group (n=11). Initial three-chamber behavioral testing began at five weeks of age to
provide baseline sociability data for each test group. A second round of behavioral testing
occurred in all test groups after three 3 weeks after KD diet administration. Final testing occurred
after 6 weeks of CD, KD, and after 5 days of reversal to CD for the KD-CD mice test group.
Mice were all fed ad libitum and all measures were taken to minimize animal suffering.

Baseline

Test

Re-Test

Figure 6: Study design timeline. All mice are male BTBR; Test 1 is a baseline at 5 weeks of age;
Test is after 3 weeks on diet; Re-Test is after 6 weeks on diet and after 5-day reversal to CD.
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Weight & Blood Analysis: Ketone and Glucose Levels
In order to measure blood, all mice were briefly anesthetized by inhalation of isoflurane,
a general anesthetic. Blood was then collected by nicking the lateral tail vein. The blood ketone
(BHB) and glucose was measured using a Precision Xtra ketone/glucose meter and strips and
recorded for each mouse. Increased blood concentration of BHB was taken as evidence of a high
concentration of ketone bodies in the blood, ketonemia, in animals fed with the KD. The mice
were placed back into their home cage to wake up and recovery from anesthesia.

Behavioral Testing
Three-Chamber Testing
The three-chamber test is used to assess sociability and self-directed repetitive behavior is
autistic mouse models. The three-chamber apparatus was made of Plexiglas and consisted of
three equally-sized chambers (42.5 cm x 19.1 cm x 22.2 cm) separated by removable doors.
These doors block entrance from the center chamber to the left and right side chambers. A wire
cage (inverted pencil cup) was set against the back wall of each of the two side chambers. These
were present for the entirety of testing. The three-chamber test is made up of two initial
habituation phases and three recorded test phases and occurs for a total duration of 40 minutes.
Before the start of a testing session, the cage of test mice were placed in the testing room, with
the cage filter lid removed, to habituate to the testing room for 30 minutes. Simultaneously, the
stranger mice (adult, male, from the same diet treatment as each test group) were placed under
the two wire cups in the apparatus and left to habituate to the cups for 10 minutes (Figure 7A).
Afterward, the stranger mice were returned to their cage and the apparatus was washed with
warm water and soap to remove the scent of the stranger mice as well as any urine and feces
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excreted from the stranger mice. Next, the subject mouse was placed in the center chamber with
the doors blocking access to both left and right chambers. This lasted for 10 minutes and allowed
the subject mouse to be familiar with the apparatus (Figure 7B). After habituation sessions for
the stranger and subject mice were completed, a video-recording camera was setup to record the
activity of the test mouse in the two 10 minute phases (Phase 1 and Phase 2) of the threechamber test for each group: CD, KD, and CD-KD reversal.
In the first recorded video session, Phase 1, the doors of the side chambers were removed
and the lid placed on top of the apparatus. The removal of the doors allowed the subject mouse to
freely explore the left and right side chambers (Figure 7C) and this phase tested for side bias. At
the end of the Phase 1 and before the start Phase 2, the subject mouse was gently guided back
into the center chamber and the doors replaced, isolated the subject mouse in the center chamber.
At this point, one stranger mouse was then placed under a wire cages in a side chamber and the
cement block was placed to hold the wire cage in place. Next, the side doors were removed to
allow the test mouse full access to the side chambers (Figure 7D). Phase 2 tested for social
preference (time the subject mouse spent in the chamber with the stranger vs. time spent alone).
At the end of the testing session, all mice were returned to their home cage and placed back in
the mouse room. The entire three-chamber apparatus, including the removable doors, wire cages
and cement blocks, was washed and dried.

Phase 2: Sociability
As mentioned above, phase 2 measures the tendency of the subject mouse to approach
another mouse and engage in social investigation. In Figure 7C, one side chamber contains a
stranger mouse that is contained in a wire cup that allows for visual, olfactory, auditory and some
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tactile contact to be made while the side chamber contains the empty wire cage. Normal, healthy,
mice are highly social animals that typically display social investigation of unfamiliar mice of
the same species while BTBR mice demonstrate autistic-like behaviors (reduced social
interactions, impaired play, low exploratory behavior) that were expected to interfere with
sociability resulting in less time spent with the test mouse.

Figure 7: Outline of the three-chamber test. (Svedova, 2011)
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Statistical Analysis
Data from the three chamber tests was scored by two independent researchers and at least
one scorer was blind to dietary treatment. These data were entered into an Excel spreadsheet then
analyzed based on time spent in each chamber. Sociability test in three-chamber Phase 2 test was
defined as the ratio of time spent in the social chamber with the stranger mouse to the total time
spent in side chambers. Mean, standard deviation, standard error of the mean and t-tests were run
on all data and graphed with SigmaPlot software.
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RESULTS
Weight & Blood: Ketone and Glucose Levels
Body weights and blood chemistry of each mouse was measured before treatment (five
weeks of age; Baseline) as well as after three weeks of diet administration (eight weeks of age;
Test) and after 6 weeks of diet administration (eleven weeks of age; Re-Test). Weight loss,
increased ketone levels, and decreased glucose levels were found in KD and Reversal groups in
the Test after 3 weeks of KD consumption. Additionally, weight, ketone, glucose levels returned
to baseline after 5-day reversal to CD.

Weight Change Compared to Baseline
6
CD
KD
Reversal

Change in Weight (g)

4

2

**
0

-2

-4

Test

Re-Test

Figure 8: This figure shows change in weights at 5 weeks of age as compared 8 and 11
weeks of age for male BTBR mice in each treatment condition: CD, KD, and KD Reversal.
There was a significant weight gain between Test and Re-Test as the Reversal group was
switched to the CD (** p < 0.01).
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Blood Ketone Levels
2.5
CD
KD
Reversal

*

2.0

Ketone (mM)

*
1.5
##
1.0

0.5

##
0.0

Baseline

Test

Re-Test

Figure 9: KD increases blood ketone levels while reversal to CD returns ketone levels to
baseline. There was a significant increase in ketone levels between the Baseline and first Test in
both the KD and Reversal groups (KD: * p < 0.05; Reversal ## p < 0.01). The KD-fed group
continued to have elevated ketone levels, while the Reversal group returned to baseline ketone
levels (KD: * p < 0.05; Reversal ## p < 0.01).
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Blood Glucose Levels
180

###

CD
KD
Reversal

Glucose (mg/dL)

160

140

120

**

100

**

###

80

Baseline

Test

Re-Test

Figure 10: KD decrease blood glucose levels while reversal to CD returns glucose levels to
baseline. There was a significant decrease in glucose levels between the baseline test and the
first Test in both the KD and Reversal groups (KD: ** p < 0.01; Reversal ### p < 0.001). The
KD-fed group continued to have decreased blood glucose levels, while the Reversal group
returned to baseline ketone levels (KD: ** p < 0.01; Reversal ### p < 0.001).
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Three-Chamber Sociability Testing
The ratio of Phase 2, preference for sociability phase, compared to Phase 1, the nonsocial phase was used to assess sociability in each treatment group: CD, KD, and Reversal. As
expected, results suggest that the CD-fed BTBR mice did not spend significantly more time with
a mouse-containing versus an empty chamber in any of the three tests, nor were the CD-fed mice
found to be asocial. The first treatment group, KD-fed mice, showed neither an overall increase
in sociability in the Test after three week of diet administration, nor in the Re-Test (after six
weeks of diet administration) with was contrary to previous findings. Similarly, the Reversal
group did not demonstrate significant changes in sociability in any of the three behavioral tests.

Time in chamber with mouse
over total time in side chambers

= Control Diet

CD-Fed BTBR Mice: Preference for Sociability
0.8
0.7
0.6
0.5
0.4
0.3

Baseline
phase 1

phase 2

Test
phase 1

phase 2

Re-Test
phase 1

phase 2

Figure 11: CD has no effect on social preference in CD-Fed male BTBR mice in three
chamber test. Figure shows that as expected, CD-fed mice had no significant behavioral
changes characterized by time in chamber with stranger mouse in Phase 2 over total time in side
chambers (n=11).
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= Control Diet
= Ketogenic Diet

Time in chamber with mouse
over total time in side chambers

KD-Fed BTBR Mice: Preference for Sociability
0.8
0.7
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0.5
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Re-Test
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phase 2

Time in chamber with mouse
over total time in side chambers

Figure 12: KD has no effect on social preference in KD-Fed male BTBR mice in three
chamber test. KD-fed male BTBR mice did not exhibit significant pro-social behavior after 3
weeks of KD (Test) or 6 weeks of KD (Re-Test) (n=12). These data conflict with previous
research findings of Ruskin et al. (2013).

Reversal BTBR Mice: Preference for Sociability
0.8
0.7
0.6
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Figure 13: Neither the KD nor Reversal to CD had a significant effect on social preference
of male BTBR mice in three chamber test. Data reveals male BTBR mice demonstrated no
significant pro-social behavior after 3 weeks of KD (Test) or after a 5-day reversal to CD (ReTest) (n=11).
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Three-Chamber Sociability Testing – Mice Social on KD
As the data does not indicate improvement in social behavior for the Reversal group in
the three chamber Test (after 3 weeks of KD) compared to sociability in Baseline test, it remains
difficult to draw conclusions regarding the persistent effects of the diet. For this reason, the mice
which demonstrated increased sociability (ratio > 0.5 in Phase 2 of the Test, after 3 weeks of KD
administration) were selectively isolated and re-analyzed.

Time in chamber with mouse
over total time in side chambers
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KD-Fed BTBR Mice: Social in Phase 2
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0.3
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Time in chamber with mouse
over total time in side chambers

Figure 14: KD increase male
BTBR sociability
during
three chamber
testing.
Data indicates
Reversal
BTBR Mice:
Social
in Phase
2
KD-fed mice spent significantly more time in the target chamber during phase 2 than phase 1 in
1.0 three weeks of KD (n=6, **p < 0.01). In the Re-Test, mice exhibited a tendency of
the Test after
increased sociability that approached significance ( + p < 0.09).
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Figure 15: KD increase male BTBR sociability, while reversal to CD has no significant
BTBR
Mice:
Social
in Phase
effect on behavior during Reversal
three chamber
testing.
Data
indicates
while on2 the KD for three
weeks (in 1.0
Test), mice spent significantly more time in the in the chamber with the stranger
mouse during phase 2 (n=5, **p < 0.01). However, after 5-day reversal to the CD, BTBR mice
0.9 significant pro-social behavior suggesting that the KD does not have persistent
exhibited no
effects on sociability.
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DISCUSSION
In this study, blood, weight, and behavioral effects of the KD on juvenile male BTBR
mice, a mouse model of autism spectrum disorder (ASD) were assessed. BTBR mice exhibit
several symptoms of autism including: reduced social interactions, impaired play, low
exploratory behavior, unusual vocalizations and high anxiety as compared to other inbred strains
(McFarlane, 2008; Moy, 2007; Scattoni, 2008). BTBR mice at 5 weeks of age were randomly
assigned to one of three diet groups: CD, KD, and Reversal. All mice underwent three-chamber
behavioral testing followed by two periods lasting three weeks. During the first period, both KD
group and KD reversal groups were switched to KD for three weeks and underwent threechamber behavioral testing. Subsequently, both groups underwent three additional weeks of KD,
however in the last 5 days of the second period the reversal group was reverted to the CD and
underwent their final three-chamber behavioral test.
It was expected that at our baseline test (five weeks of age) all dietary treatment groups
would be non-social, as they had been on the CD. After three weeks of diet administration (eight
weeks of age), it was expected that the CD group would remain non-social while the KD and
Reversal groups would demonstrate pro-social behaviors as previous studies have indicated that
KD-fed BTBR mice showed behavioral improvements including an increased sociability in a
three-chamber test after simply three weeks of diet administration (Ruskin et al., 2013). Finally,
after six weeks of diet administration (11 weeks of age), it was expected that the CD would again
remain non-social, the KD and Reversal groups would maintain their pro-social behaviors. The
idea of a continued, or persistent, effect of the diet was rooted in previous lab findings that mice
on the diet for 12 weeks demonstrated lasting positive behavioral alterations after a 5-day dietary
reversal.
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Our initial expectation that all male BTBR mice would demonstrate non-social behaviors
was supported by our data. Additionally, as expected, our study found significant impact of the
KD on blood levels and weight change; just three weeks after KD administration, in our second
behavioral test, result show a significant increase in ketone levels and significant decrease in
glucose levels for both KD and Reversal groups. Results for the Re-Test, 5 days after reversal to
the CD, results indicate the reversal group is no longer in ketosis. Although our blood analysis
revealed the hallmark characteristics of KD treatment, including weight loss, decreased glucose,
and increased ketone levels, we did not successfully replicate the pro-social effects of the KD on
behavior previously found by Ruskin et al. (2013, and unpublished data). Even when the mice
that demonstrated pro-social behavior after three weeks on the diet in phase 2 of the behavioral
test were isolated, there was only a slight hint that the KD had effect on behavior in the KD
group. In the Reversal group, despite a significant appearance of pro-social behavior after three
weeks on the diet, the mice fell back to baseline non-social behavior once they were switched to
the KD. In sum, our results suggest the KD does not have persistent effects on sociability.
It is unclear why we were unable to replicate improvement in sociability, which has been
demonstrated in the laboratory setting on multiple replications. Some ideas include the
composition of our KD distributed by the company BioServ. One thought is that ingredients
making up the 6:1 ratio of the KD may have been altered or the provider for the ingredients may
have changed. Additionally, it is known that in any behavioral testing the external environment
including temperature, lighting, noise, and scents can have a profound effect on animal behavior.
Specifically, exposure to scents in a lab setting has been impacted in changing the social status
and competitive in inbred male mice, including BTBR mouse models (Bine et al., 2013). It could
be proposed that a change in environment may have induced a stress response in our mouse
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models and thereby affected the pro-social effects of the KD. Additionally, in the unpublished
laboratory data presented in in Figure 7, the persistent effect is based on a single three-chamber
test after a 5-day reversal. This is in contrast with our methodology in which three behavioral
tests were run. It is possible that the increased behavioral testing influenced behavior within our
population of BTBR mouse models.
As we move forward with this study, it is important to consider other behavioral tests for
ASD-like behaviors. The core symptoms of autism include persistent social communication
impairment and restricted and repetitive patterns of behavior. In this study, a single method of
behavioral testing was used to assess sociability, however many other methods exist to test the
social deficits that are characteristic of ASD including frontal contact analysis of the existing
three-chamber videos and social transmission of food preference (STFP) tasks. STFP tests for
social learning and the ability of a test mouse to observe and detect olfactory cues on a stranger
mouse and learn to prefer a certain food based on the scent (Wrenn, 2004). Frontal contact is a
measure of preference of reciprocal social interaction (Silverman et al., 2010). It was found that
after three weeks on the KD, Ruskin et al. (2013) noted that male BTBR fed the KD had
improved communication as they were trained to prefer a food based on social interaction and
demonstrated a significant increase in frontal contact with stranger mice as compared to control
diet-fed mice.
In addition, the BTBR mouse strain has been shown to have abnormally high repetitive
behaviors, namely grooming including in the three-chamber test. KD treatment has been shown
to reduce these behaviors; therefore, it is possible to go back and reanalyze current video scores
for grooming behavior. For this measure, we score for cumulative time spent grooming all body
regions to analyze repetitive patterns. In terms of self-directed repetitive behavior, BTBR mice
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fed the KD spent significantly less time grooming in both phase 2 of the three-chamber which
suggested an improvement of one of the core symptoms of ASD (Ruskin et al., 2013).
In the future, research regarding the diet reversal and persistent effects of the KD on
autistic symptoms of BTBR mouse models may use a modified experiment timeline. Ours was
modeled after the experiment conducted by Lusardi et al. (2105) that demonstrated rodents fed
the KD for fifteen weeks showed a prolonged reduction of seizures which continued after a 4day reversal to control diet. Ongoing research may increase length of diet administration prior to
reversal which may allow for increase epigenetic changes to take place. It would be interesting to
use methods of detecting epigenetic markers, such as DNA methylation assay, to gather total
genomic DNA from frozen tissue and assess global DNA methylation of KD and Reversal
treatment groups compared to the CD group (Williams-Karnesky et al., 2013). This would
provide evidence for changes that may be induced by the diet but do not affect behavior. Subtle,
yet effective changes to study design may include a larger sample size and including additional
measures of sociability including frontal contact and self-directed repetitive behaviors.
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CONCLUSION
This study focused on the BTBR mouse model to determine if improvement in ASDassociated behaviors persists when animals are returned to a CD. Despite ketone, glucose, and
weight changes data that represent hallmark characteristics of an effective KD treatment, we did
not find significant improvements in sociability in either KD or Reversal groups. Further analysis
of social animals in behavioral tests (after three weeks of diet administration) and Re-Test (after
six weeks of diet administration) reveals a trend of pro-social effects of the diet in KD-fed group,
however results do not provide support that increased sociability persists after diet
administration. Ongoing research will focus on additional measures off sociability including
frontal contact and self-directed repetitive behaviors.
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